Silence Therapeutics appoints ex-Akari CEO in top position
pharmafile | July 17, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Akari, CEO, Sanofi, Silence Therapeutics, zealand
Silence Therapeutics has appointed Dr David Horn Solomon as its new Chief Executive Officer (CEO), effective immediately. Solomon will head the RNA therapeutics firm’s leadership team and join the company’s Board of Directors.
Solomon, an experienced public company biotech CEO, board member and biotech investor, led Zealand Pharma as CEO from 2008 to 2015. During this period, Zealand’s lead product Adlixin, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved within the US and around the globe. The drug is now marketed by French multinational Sanofi.
Commenting on the appointment, Annalisa Jenkins, Executive Chair of Silence Therapeutics, said: “I am thrilled to be welcoming David to lead the Company through its next phase of growth. Having held senior management roles in both the US and Europe, David brings extensive international leadership experience in the biotech industry with a track record of successful pipeline delivery, financing and deal making. Silence is now a leading RNAi company building the next generation of programmes based upon our proprietary technology platform in GalNAc-conjugated siRNA. With David at the helm as CEO, supported by a very experienced team and Board, Silence is in a strong position to maximise the potential of our IP and technology through strong collaborations and the advancement of our internal programmes toward the clinic, with our lead candidate SLN124 becoming a clinical stage asset in the coming year.”
Solomon has also led Bionor Pharma and Akari Therapeutics as CEO. However Solomon resigned from his position at the latter firm in May of this year, following allegations that he had violated company policy through the use of company credit cards for personal transactions.
Solomon studied at Cornell University’s medical school and its Graduate School of Medical Sciences, from which he received a PhD. He subsequently served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City before heading healthcare investment at Carrot Capital Healthcare Ventures in New York.
Solomon himself added: “In this age of RNAi, Silence’s world class RNAi platform offers an exciting opportunity to build a competitive drug development company with global relevance. I am particularly impressed with the near-term opportunities including the lead programme in iron overload disorders which is progressing toward clinical trials. I am very pleased to join Silence at this critical juncture for both the sector and patients. I look forward to working with the highly accomplished Leadership Team and Board of Directors as we translate the excellent science into meaningful value for both patients and investors.”
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …